Browse studies

Find your next paid study

298 recruiting studies matching your filters

MC1684 Phase I Trial of Systemic Administration of Vesicular Stomatitis Virus Genetically Engineered to Express NIS and Human Interferon, in Patients With Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia, Lymphomas, or Histiocytic/Dendritic Cell Neoplasms

This phase I trial studies the best dose and side effects of the VSV-hIFNβ-NIS vaccine with or without cyclophosphamide and combinations of ipilimumab, nivolum…

B-Cell Non-Hodgkin LymphomaHistiocytic and Dendritic Cell NeoplasmMyelodysplastic Syndrome+16 more

Estimated

~$10 – $6,250

Mayo ClinicNCT03017820

Phase 1

A Phase 1 With Extension Cohort, Single Arm, Single Center, Open Label Trial of Belantamab Mafodotin for the Treatment of High-Risk Smoldering Multiple Myeloma (BELLA)

This is a single-center, single arm, phase I study designed to determine the safety and find the recommended Phase 2 dose (RP2D) or maximum dose level (MTD) of…

Myeloma

Estimated

~$10 – $6,250

M.D. Anderson Cancer CenterNCT05055063

Phase 3

A Phase III Randomized Trial for Newly Diagnosed Multiple Myeloma (NDMM) Patients Considered Frail or in a Subset of "Intermediate Fit" Comparing Upfront Three-Drug Induction Regimens Followed by Double or Single-Agent Maintenance

This phase III trial compares three-drug induction regimens followed by double-or single-drug maintenance therapy for the treatment of newly diagnosed multiple…

Plasma Cell Myeloma

Estimated

~$10 – $7,500

SWOG Cancer Research NetworkNCT05561387

Phase 1

A Phase I Trial Evaluating Escalating Doses of ²¹¹At-Labeled Anti-CD38 Monoclonal Antibody Followed by HLA-Matched or Haploidentical Donor Hematopoietic Cell Transplantation for High-Risk Multiple Myeloma

This phase I trial investigates the side effects and best dose of ²¹¹At-OKT10-B10 when given together with fludarabine, alone or in combination with cyclophosp…

Multiple MyelomaRecurrent Multiple MyelomaRefractory Multiple Myeloma

Estimated

~$10 – $6,250

Fred Hutchinson Cancer CenterNCT04579523

Phase 2

A Phase 2 Trial of Leflunomide, Pomalidomide, and Dexamethasone for Relapsed/Refractory Multiple Myeloma

This phase II trial studies how well leflunomide, pomalidomide, and dexamethasone work for the treatment of multiple myeloma that has come back (relapsed) or d…

Recurrent Plasma Cell MyelomaRefractory Plasma Cell Myeloma

Estimated

~$10 – $6,250

City of Hope Medical CenterNCT04508790

Neurocognitive Outcomes After Whole Brain Radiation Therapy for Hematologic Malignancies

This study assesses neurocognitive outcomes after receiving radiation therapy to the brain (whole brain radiation therapy) in patients with blood cancers (hema…

Central Nervous System LymphomaHematopoietic and Lymphoid Cell NeoplasmLeukemia+3 more

Estimated

~$10 – $750

M.D. Anderson Cancer CenterNCT05011045

Observational

Feasibility and Preliminary Efficacy of GPT-QPL: An AI-Generated, Personalized Question Prompt List Intervention for Patients With Hematologic Cancers

The goal of this study is to evaluate the feasibility and preliminary efficacy of an artificial intelligence (AI)-generated personalized question prompt list (…

LymphomaMultiple Myeloma

Estimated

~$10 – $6,250

Washington University School of MedicineNCT07226934

Observational

Intervention to Enhance Cognitive Augmentation and Neuroplasticity (I-CAN)

This clinical trial evaluates whether an online cognitive training intervention (Intervention to enhance Cognitive Augmentation and Neuroplasticity \[I-CAN\]),…

Recurrent B-Cell Non-Hodgkin LymphomaRecurrent Multiple MyelomaRefractory B-Cell Non-Hodgkin Lymphoma+1 more

Estimated

~$10 – $6,250

Ohio State University Comprehensive Cancer CenterNCT07609030

Phase 2

Frontline T-cell Engager vs Autologous Stem Cell Transplant and Measurable Residual Disease (MRD)-Guided Sequential Intensification thERapy in Multiple Myeloma (FASTER)

This is an open-label, multi-site, Phase II randomized trial with response-adaptive design for newly diagnosed multiple myeloma (NDMM) participants who have ha…

Multiple Myeloma, Newly DiagnosedMultiple Myeloma (MM)

Estimated

~$10 – $8,750

SCRI Development Innovations, LLCNCT06974786

Phase 2

Efficacy of Curcumin and Piperine in Patients on Active Surveillance for Either Monoclonal Gammopathy of Unknown Significance (MGUS), Low-risk Smoldering Multiple Myeloma (SMM) or Early Stage Prostate Cancer: A Pilot Study

To explore the use of curcumin and piperine supplementation at a dose of 4 gram/5mg twice a day in early stage prostate cancer patient undergoing active survei…

Prostate CancerMultiple MyelomaSmoldering Multiple Myeloma (SMM)+1 more

Estimated

~$10 – $6,250

University of RochesterNCT04731844

Protocol for Transgene Assay Service

The purpose of this transgene assay testing service is to evaluate tumor samples for transgene levels in patients who received a commercially available Bristol…

Non-Hodgkin LymphomaChronic Lymphocytic LeukaemiaMultiple Myeloma

Estimated

~$10 – $7,500

Bristol-Myers SquibbNCT06357754

cfDNA Assay Multicenter Prospective Observational Validation for Early Cancer Detection, Minimal Residual Disease, and Relapse

This is an observational case-control study to train and validate a genome-wide methylome enrichment platform to detect multiple cancer types and to differenti…

Brain CancerBreast CancerBladder Cancer+17 more

Estimated

~$10 – $1,050

Adela, IncNCT05366881